RELATIONSHIP BETWEEN CLINICAL STATUS, QUALITY OF LIFE AND PHYSICAL EXERCISE TOLERANCE INDICATORS WITH BIOMARKERS IN PATIENTS WITH CARDIORENAL SYNDROME
Keywords:
cardiorenal syndrome, clinical status assessment scale, quality of life, MLHFQ, 6-minute walk test, NYHA functional class, physical exercise, biomarkers, correlation analysis.Abstract
The article presents a comprehensive assessment of the relationship between clinical status (CSAS), quality of life (MLHFQ), and physical exercise tolerance (6-minute walk test — 6MWT) indicators with biomarkers in cardiorenal syndrome (CRS) developed against the background of chronic heart failure (CHF). The study included 240 participants: Group 1 — with CRS (n=100), Group 2 — CHF without CRS (n=100), Group 3 — control (n=40). In the CRS group, the CSAS score was 7.2±0.2 (control: 1.2±0.1, 6-fold higher), MLHFQ score — 56.4±1.7 (control: 8.5±0.8, 6.6-fold higher — low quality of life), 6MWT — 262±10 m (control: 525±14, 2-fold lower). G/G genotype carriers showed the most severe clinical course: CSAS — 7.9, MLHFQ — 61.6, 6MWT — 225.8 m (vs A/A; p<0.001). Correlations were established between 6MWT and uromodulin (r=+0.69), MLHFQ and uromodulin (r=−0.71), CSAS and NT-proBNP (r=+0.72). 4 diagrams and 2 tables are presented.
References
Bocchi E.A., Cruz F., Guimarães G., et al. Long-term prospective, randomized, controlled study using repetitive education at six-month intervals and monitoring for adherence in heart failure outpatients: the REMADHE trial. Circ Heart Fail. 2008;1(2):115–124.
Guha K., McDonagh T. Heart failure epidemiology: European perspective. Curr Cardiol Rev. 2013;9(2):123–127.
Mareev V.Yu., Belenkov Yu.N., Ageev F.T. Шкала оценки клинического состояния (ШОКС) при ХСН. Сердечная Недостаточность. 2000;1(3):109–112.
Rector T.S., Kubo S.H., Cohn J.N. Patients' self-assessment of their congestive heart failure. Heart Fail. 1987;3:198–209.
Guyatt G.H., Sullivan M.J., Thompson P.J., et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132(8):919–923.
Bilbao A., Escobar A., García-Perez L., Navarro G., Quirós R. The Minnesota living with heart failure questionnaire: comparison of different factor structures. Health Qual Life Outcomes. 2016;14:23.
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117.
Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129–2200.
Köttgen A., Hwang S.J., Larson M.G., et al. Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol. 2010;21(2):337–344.
Padmanabhan S., Melander O., Johnson T., et al. Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet. 2010;6(10):e1001177.
Wuttke M., Li Y., Li M., et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat Genet. 2019;51(6):957–972.
Damman K., Valente M.A., Voors A.A., et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455–469.
Garin O., Soriano N., Ribera A., et al. Validation of the Spanish version of the Minnesota Living with Heart Failure Questionnaire. Rev Esp Cardiol. 2008;61(3):251–259.
Garin O., Herdman M., Vilagut G., et al. Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measures. Heart Fail Rev. 2014;19(3):359–367.
Spertus J.A., Jones P.G. Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire. Circ Cardiovasc Qual Outcomes. 2015;8(5):469–476.
Behnoush A.H., Khalaji A., Bahiraie P., et al. Quality of life in heart failure: a systematic review. Heart Fail Rev. 2023;28(6):1397–1420.
LaFavers K.A., Macedo E., Garimella P.S., et al. Circulating uromodulin inhibits systemic oxidative stress by inactivating the TRPM2 channel. Sci Transl Med. 2019;11(512):eaaw3639.
